Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA21004 vs placebo in elderly major depressive disorder
2008-002901-38Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoints: Change in HAM-D24 total score at Week 8 and Safety and tolerability of Lu AA21004 5 mg. Started Oct 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-002901-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002901-38.